An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and Efficacy of ALN-PCSSC in Subjects With Homozygous Familial Hypercholesterolemia

Trial Profile

An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and Efficacy of ALN-PCSSC in Subjects With Homozygous Familial Hypercholesterolemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Inclisiran (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Therapeutic Use
  • Acronyms ORION-2
  • Sponsors The Medicines Company
  • Most Recent Events

    • 16 May 2017 Planned End Date changed from 1 May 2018 to 31 Dec 2018.
    • 16 May 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
    • 08 Jan 2017 Status changed from not yet recruiting to recruiting, as reported in the Medicines Company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top